Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 4
2014 3
2015 1
2019 2
2020 6
2021 4
2022 6
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean shigemori furukawa (2 results)?
Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis.
Nomura S, Watanabe T, Honma R, Matsukura S, Ito E, Imai JI, Kiko Y, Suzuki O, Hashimoto Y, Kojima M, Furukawa S, Soeda S, Watanabe S, Fujimori K. Nomura S, et al. Among authors: furukawa s. Fukushima J Med Sci. 2024 Mar 15. doi: 10.5387/fms.23-00011. Online ahead of print. Fukushima J Med Sci. 2024. PMID: 38494731 Free article.
SPON1 is an independent prognostic biomarker for ovarian cancer.
Miyakawa R, Kobayashi M, Sugimoto K, Endo Y, Kojima M, Kobayashi Y, Furukawa S, Honda T, Watanabe T, Asano S, Soeda S, Hashimoto Y, Fujimori K, Chiba H. Miyakawa R, et al. Among authors: furukawa s. J Ovarian Res. 2023 May 13;16(1):95. doi: 10.1186/s13048-023-01180-8. J Ovarian Res. 2023. PMID: 37179355 Free PMC article.
Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab:A case report.
Kojima M, Soeda S, Okabe C, Sato T, Kamo N, Ueda M, Endo Y, Nomura S, Tokuda E, Furukawa S, Kataoka M, Fujita S, Saji S, Watanabe T, Fujimori K. Kojima M, et al. Among authors: furukawa s. Fukushima J Med Sci. 2022 Dec 21;68(3):191-195. doi: 10.5387/fms.2022-10. Epub 2022 Nov 9. Fukushima J Med Sci. 2022. PMID: 36351631 Free PMC article.
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T, Takatori E, Nagasawa T, Kagabu M, Baba T, Shigeto T, Matsumura Y, Shimizu D, Terada Y, Seino M, Ohta T, Nagase S, Shigeta S, Tokunaga H, Shimada M, Kaiho-Sakuma M, Furukawa S, Soeda S, Watanabe T, Takahashi F, Yokoyama Y. Shoji T, et al. Among authors: furukawa s. Int J Clin Oncol. 2022 Dec;27(12):1874-1880. doi: 10.1007/s10147-022-02246-1. Epub 2022 Oct 10. Int J Clin Oncol. 2022. PMID: 36214925
Claudin‑9 is a novel prognostic biomarker for endometrial cancer.
Endo Y, Sugimoto K, Kobayashi M, Kobayashi Y, Kojima M, Furukawa S, Soeda S, Watanabe T, Higashi AY, Higashi T, Hashimoto Y, Fujimori K, Chiba H. Endo Y, et al. Among authors: furukawa s. Int J Oncol. 2022 Nov;61(5):135. doi: 10.3892/ijo.2022.5425. Epub 2022 Sep 21. Int J Oncol. 2022. PMID: 36129146 Free PMC article.
Rare Hereditary Gynecological Cancer Syndromes.
Watanabe T, Soeda S, Endo Y, Okabe C, Sato T, Kamo N, Ueda M, Kojima M, Furukawa S, Nishigori H, Takahashi T, Fujimori K. Watanabe T, et al. Among authors: furukawa s. Int J Mol Sci. 2022 Jan 29;23(3):1563. doi: 10.3390/ijms23031563. Int J Mol Sci. 2022. PMID: 35163487 Free PMC article. Review.
29 results